The dystrophin gene is alternatively spliced throughout its coding sequence  by Sironi, M et al.
The dystrophin gene is alternatively spliced throughout its coding
sequence
M. Sironia;, R. Cagliania, U. Pozzolia, A. Bardonia, G.P. Comib, R. Giordaa, N. Bresolina;b
aIRCCS E. Medea, Associazione La Nostra Famiglia, Via Don Luigi Monza 20, 23842 Bosisio Parini (LC), Italy
bCentro Dino Ferrari, Istituto di Clinica Neurologica, Universita' di Milano, IRCCS Ospedale Maggiore Policlinico, Milan, Italy
Received 6 March 2002; accepted 13 March 2002
First published online 28 March 2002
Edited by Lev Kisselev
Abstract We have analysed splicing patterns in the human
dystrophin gene region encoding the rod and cysteine-rich
domains in normal skeletal muscle, brain and heart tissues.
Sixteen novel alternative transcripts were identified, the majority
of them being present in all three tissues. Tissue-specific variants
were also identified, suggesting a functional role of transcrip-
tional diversity. Transcript analysis in dystrophinopathic autop-
tic and bioptic specimens revealed that pre-mRNAs secondary
structure formation and relative strength of exon/exon associa-
tion play little or no role in directing alternative splicing events.
This analysis also showed that independent deletion events
leading to the loss of the same exons may be associated with
transcriptional variability. ß 2002 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Dystrophin is the largest known human gene: it extends
over 3000 kb on the X chromosome [1] and is transcribed
into a 14-kb mRNA [2]. The gene is composed of 79 exons
that together account for only 0.6% of the sequence [3]. Its
main protein product, dystrophin, a member of the spectrin
superfamily, is a rod-shaped 427-kDa protein [3]. In skeletal
muscle dystrophin localises to the cytoplasmic surface of the
sarcolemma where it is thought to provide a link between
cytoskeletal actin and the extracellular matrix.
Three full-length dystrophin isoforms have been described,
each controlled by a tissue-speci¢c promoter [4^6]. The muscle
isoform is mainly expressed in skeletal muscle but also in
smooth and cardiac muscles [7] ; brain dystrophin is speci¢c
for cortical neurons but can also be detected in heart and
cerebellar neurons, while the Purkinje-cell type accounts for
nearly all cerebellar dystrophin [6]. Alternative splicing pro-
vides a means for dystrophin diversi¢cation: the 3P region of
the gene undergoes alternative splicing resulting in tissue-spe-
ci¢c transcripts in brain neurons, cardiac Purkinje ¢bres, and
smooth muscle cells [7,8] while 12 patterns of alternative splic-
ing have been described in the 5P region of the gene in skeletal
muscle [9].
Mutations in the dystrophin gene are responsible for either
Duchenne or Becker muscular dystrophy (DMD or BMD).
The majority of DMD and BMD patients carry deletions in
the gene (60^65% of cases) [7] and a good correlation exists
between the severity of the muscle disease and the e¡ect of the
deletion on the reading frame [10]. However exceptions to the
reading frame rule are found in about 8% of patients [11] and
the possibility that alternative splicing events could modify the
clinical phenotype of DMD and BMD by editing the transla-
tional reading frame has been proposed [12,13]. A major hot
spot for DMD/BMD deletions has been identi¢ed around
exons 45^55; the existence of alternative splicing events in
this region of the gene has never been investigated. Here we
provide description of dystrophin transcripts arising from al-
ternative splicing events in the region encoding the rod and
cysteine-rich domains. In DMD and BMD, muscle involve-
ment can be associated with heart disease and/or mental re-
tardation; in this view, transcript analysis was extended to
human brain and heart tissues.
2. Materials and methods
Tissue samples were derived, with informed consent of the family,
from either autopsies or muscle biopsies of healthy individuals and
DMD/BMD patients. Patient selection followed standard internation-
al criteria and dystrophin gene deletion analysis was performed using
routine procedures. Total RNA was extracted from frozen specimens
using RNAzolB (Biotecx) in accordance with the manufacturer’s spec-
i¢cations. RT-PCR for cDNA synthesis was performed using random
hexamers and 1st strand cDNA synthesis kit (Boehringer). Exons 37^
38 of the dystrophin gene were ampli¢ed from each sample in order to
verify the ability of the cDNA to act as a template for dystrophin
ampli¢cation. Six nested primer pairs were used to amplify dystrophin
exons 17^58, as previously described [14]. Sixteen additional primers
were designed to speci¢cally amplify splice variants (sequences are
available on request). PCR fragments were separated on 2% agarose
gels; after puri¢cation, the ampli¢ed products were sequenced using
the same primers as used for PCR ampli¢cation and BigDye1 termi-
nator cycle sequencing (PE Applied Biosystems) on an ABI PRISM
310 genetic analyzer. Exonic splicing enhancer (ESE) scores were cal-
culated for dystrophin exons using ESE scoring matrices as previously
described [15,16]. Matrices were slightly modi¢ed as suggested by the
authors (personal communication).
3. Results and discussion
Analysis of dystrophin alternative splicing events in the
region encompassing exons 17^58 was performed for human
skeletal muscle, brain and heart tissues. Spliced products were
ampli¢ed with nested primer pairs from normal human tissues
and directly sequenced in order to determine their exact exon
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composition. As nested PCR ampli¢cations often resulted in a
complex transcript pattern (Fig. 1A), speci¢c primers were
designed on the basis of the novel exonic junctions and new
selective ampli¢cations were carried out to con¢rm the pres-
ence of the alternatively spliced variants and to better assess
their tissue speci¢city. Selective ampli¢cations for skeletal
muscle, brain and heart tissues are shown in Fig. 1B. The
presence of each alternative transcript was con¢rmed in tis-
sues from at least two unrelated subjects. A total of 16 alter-
native transcripts were identi¢ed, the majority of them being
present in all three tissues (Table 1). Tissue-speci¢c splice
variants were also identi¢ed: skipping of exons 39 and 42
was speci¢c for brain and heart, while transcripts lacking
exons 45^49 were only detectable in skeletal and cardiac
muscles. Loss of exons 41^42 was restricted to brain while
omission from dystrophin mRNA of exons 45^50 was speci¢c
for brain and muscle and was never detected in heart. Spliced
variants displayed a great variability with respect to the num-
ber of missing exons with some of them skipping up to 13
exons.
Interestingly, when the reading frame of all alternatively
spliced gene products was determined, only one of them,
namely the transcript lacking exons 45^50, was predicted to
be translated into a truncated dystrophin, while all the other
products preserved the reading frame. An extensive study of
alternative splicing events in the 5P region of the gene [9]
revealed that only 50% of alternative products maintained
the transcriptional reading frame of the full-length dystrophin
transcript. Reading frame analysis of alternative transcripts
might provide information concerning whether they are likely
to serve any physiological role or they are merely the results
of splicing errors. If the latter were the case, one could expect
to ¢nd in- or out-of-frame transcripts in a proportion re£ect-
ing exon codon phases in the gene, that is intron insertion
patterns with respect to the codon position in reading frames.
Since the only phase constraint is between two consecutive
exons, reading frames of products derived from omission of
one, two or more exons can be calculated and are expected to
be a result of the number of di¡erent exon phases and of exon
distribution along the gene. Frames of all possible products
originating from skipping of one up to 10 consecutive exons
were calculated for the regions of the dystrophin gene encom-
passing exons 1^18 and exons 19^58 (Table 2); a di¡erent
expectation of in-frame products is observed in the two gene
regions with the 5P portion presenting a percentage of in-
frame products ranging from 44.4% to 75% and the central
part a percentage ranging from 57.5% to 84.6%, depending on
the number of skipped exons. These gene features might par-
tially account for the di¡erent ratio of in-frame vs out-of-
frame products detectable in di¡erent gene regions. Yet, our
data indicate that, in the region under analysis, frame-shifted
transcripts are de¢nitely under-represented even when exon
codon phases are considered. These ¢ndings might suggest
that alternative splicing does not proceed at random and
that alternative variants might serve specialised cellular func-
tions, maybe irrespective of frame conservation or alteration.
Indeed, the hypothesis cannot be rejected that out-of-frame
transcript might have a biological role as well. Remarkably,
here we show evidence that skipping of exons 45^50, which
originates an out-of-frame product, is restricted to muscle and
brain. Previously described dystrophin transcripts originating
from alternative splicing events were always shown to be in-
frame when displaying tissue speci¢city [7,8] ; this is consistent
with the notion that various molecular species might serve
diverse roles in di¡erent tissues. The identi¢cation of an
out-of-frame transcript displaying some degree of tissue spec-
i¢city might suggest that production of frame-shifted tran-
scripts is a regulated process and not the result of random
processing. Interestingly, the widest range of di¡erent dystro-
phin transcripts could be detected in brain (Table 1); it is
tempting to speculate that the high complexity, in terms of
biological processes, of this tissue also carries along the need
for multiple dystrophin gene products.
Fig. 1. RT-PCR ampli¢cation of dystrophin alternatively spliced
transcripts in human skeletal muscle, brain and heart. A: Ampli¢ca-
tion of splice variants using nested PCR set 7 (exons 43^51). B: Se-
lective ampli¢cations using transcript-speci¢c primers. Lane headings
indicate skipped exons.
Fig. 2. ESE representation in single dystrophin exons. The entire
bar length indicate total ESE potential; relative length of di¡erent
segments indicate scores for four di¡erent SR protein recognition
sequences; dark grey: SF/ASF; light grey: SRp40; hatched:
SRp55; horizontal lines: SC35. ESE positions in dystrophin introns
were not included, as they are not pertinent to this study, but are
available on request.
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Extensive studies of splicing mechanisms in human genes
have allowed many of the principal elements that determine
exon inclusion in the mature transcript to be elucidated. We
considered 3P and 5P consensus values and U1 snRNA anneal-
ing free energies for the dystrophin gene region under analysis
(data not shown) as previously calculated [17]; we found that
these parameters provide no reasonable explanation concern-
ing exon skipping in alternative transcripts. Recently, SR pro-
teins, which bind ESE, have been shown to promote exon/
exon associations [18] suggesting that they might be important
for the selection of exon pairs during alternative splicing. We
applied ESE scoring matrices [15,16] to single dystrophin
exons in order to de¢ne their potential for SR protein binding.
In particular, ESE analysis scored binding potentials for the
di¡erent SR proteins identi¢ed to date; it is evident from Fig.
2 that ESE representation in di¡erent exons cannot account
for the observed splicing patterns: in many cases exons that
were found to be skipped in at least one alternative transcript
displayed high SR protein binding potentials. Nonetheless,
di¡erent molecular mechanisms, which do not rely on speci¢c
sequence elements, might account for exon skipping in mature
transcripts. mRNA secondary structure formation might have
a role in this process, maybe bringing into close proximity
splice sites separated by huge physical distances or sequester-
ing skipped exons into a loop. Also, exon skipping might be
expected to be in£uenced by the order of intron removal in a
given gene region, in particular when skipping of multiple
adjacent exons is considered. Intron removal is orderly but
not processive from the 5P to the 3P end of precursor
mRNA [19,20]; slow and fast splicing events exist that give
rise to di¡erent major and minor pathways with a preferred
order of intron removal. Further information concerning
splicing mechanisms might be gained by the analysis of pre-
cursor mRNAs carrying variations in exon composition. We
selected 14 patients carrying deletions in the dystrophin gene
and veri¢ed the presence of alternative products in their skel-
etal muscles. Deletions involved exons either skipped in alter-
native transcripts or immediately £anking alternatively spliced
Table 2
Frame of all possible products deriving from skipping of one up to 10 consecutive exons
Skipped exons
1 2 3 4 5 6 7 8 9 10
IF%a (exons 1^18) 52.9% 50.0% 46.7% 50.0% 69.2% 66.7% 45.5% 50.0% 44.4% 75.0%
IF% (exons 19^58) 57.5% 84.6% 60.5% 70.3% 66.7% 71.4% 70.6% 69.7% 75.0% 64.5%
aIF%: percentage of in-frame products.
Table 1
Analysis of alternative splicing events
aPCR sets followed a previous designation [14]; spanned exons are in parentheses.
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regions. Data concerning splicing patterns in dystrophic
muscles are reported in Table 1. When possible, two or three
patients carrying the same deletion were analysed. Remark-
ably, splicing patterns di¡ered according to the location or
extension of deletion mutations in the dystrophin gene and,
in some instances, also among patients carrying the same de-
letion. Surprisingly short deletions were found to abolish
splicing variants that longer, overlapping deletions did not.
In particular, deletions involving exons 46^48 determined
loss of transcripts lacking exons 45^49 and 45^50, while dele-
tion of exons 45^48 had no e¡ect on these products. Similarly,
deletions of exon 48 and of exons 45^47 abolished skipping of
exons 45^53 while deletions of exons 45^48 preserved this
product. These data suggest that secondary structure forma-
tion on dystrophin pre-mRNAs plays no or little role in di-
recting alternative splicing events. Moreover, loss of some
splicing variants as a consequence of mutations deleting part
of skipped exons indicates that factors other than the relative
strength of exon/exon association might be involved in direct-
ing splicing patterns. Conversely, these evidences might be
consistent with the hypothesis that the di¡erent splicing prod-
ucts re£ect minor and major splicing pathways in the dystro-
phin gene.
In two cases patients carrying the same exonic deletion
displayed di¡erent splicing behaviours with respect to the
loss or preservation of alternative transcript lacking exons
44^56 (see Table 1). This is not surprising since apparently
similar deletions are supposed to have di¡erent extension in
£anking introns and, consequently, to have a diverse impact
on splicing mechanisms. Indeed, given the tissue speci¢city of
splicing patterns, the same deletion might also be expected to
originate diverse e¡ects in di¡erent tissues. Transcript analysis
was extended to skeletal muscle, brain and heart tissues de-
rived from a DMD patient carrying a deletion of exons 45^
52: a di¡erent pattern of alternative transcripts was detectable
in the three tissues (Table 1 and Fig. 3). In particular, brain
and heart tissues of this patient preserved both the transcript
lacking exons 44^56 and the one lacking exons 45^53, while
this latter product could not be detected in skeletal muscle.
For both BMD and DMD, considerable variability in dis-
ease presentation is found across patients carrying the same
mutation and, in both pathologies, muscle involvement can be
associated with heart disease and/or mental retardation; none-
theless these manifestations seem not to be consistent with the
severity of the muscular phenotype. Our data indicate that
alternative splicing events are di¡erentially regulated in di¡er-
ent organs and that deletions involving the same exons can
determine diverse splicing behaviours in di¡erent patients or
even in di¡erent tissues of the same individual. In this view,
allelic di¡erences and tissue speci¢city in splicing factors
should be regarded as possible determinants of disease expres-
sion and di¡erential organ involvement.
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Fig. 3. Transcript analysis in tissues from patient 15. Splice variant-
speci¢c primers were used. Skipped exons are indicated on the right
together with the exons ampli¢ed in the control reaction (exons 37^
38).
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